Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 210 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Valve Replacement Clear all
Not listed Not applicable Interventional

Caisson Transcatheter Mitral Valve Replacement (TMVR)

NCT03661398
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Failure, Mitral Disease, Valve Heart Disease, Valve Disease, Heart
Interventions
Transcatheter Mitral Valve Replacement
Device
Lead sponsor
Caisson Interventional LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
View directory record Official record
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System

NCT06183684
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Laplace TTVR System
Device
Lead sponsor
Laplace Interventional, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
10
States / cities
Tucson, Arizona • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Not listed No phase listed Observational

Outcomes of Pulmonary Valve Replacement With the INSPIRIS (Model 11500A) Valve

NCT05986396
View directory record Official record
Conditions
Heart Valve Prosthesis
Interventions
INSPIRIS Resilia (model 11500A)
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 11, 2026, 4:37 AM EDT
Completed No phase listed Observational

Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device

NCT02099942
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
V8 Balloon Aortic Valvuloplasty (BAV) Catheter
Device
Lead sponsor
InterValve, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Minneapolis, Minnesota • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Neuroprotection in Patients Undergoing Aortic Valve Replacement

NCT02389894
View directory record Official record
Conditions
Aortic Stenosis, Brain Infarction, Cerebrovascular Accident, Stroke
Interventions
Embol-X Embolic Protection Device, CardioGard Cannula
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting No phase listed Observational

COMPASSION S3 Post-Approval Study

NCT04860765
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Interventions
SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex and Decreased Time to Extubation

NCT03196167
View directory record Official record
Conditions
Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Interventions
Sugammadex, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

TTVR Early Feasibility Study

NCT04433065
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Intrepid™ TTVR System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Outcomes After Albumin Vs Lactated Ringer's Solution in CABG and AVR Procedures

NCT04652375
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Aortic Valve Replacement
Interventions
Albumin Solution, Lactated Ringer's Solution
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional Results available

PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

NCT02675114
View directory record Official record
Conditions
Aortic Stenosis
Interventions
SAVR, SAPIEN 3 THV
Procedure · Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)

NCT05541679
View directory record Official record
Conditions
Complete Heart Block, High Degree Second Degree Atrioventricular Block, Pacemaker-Induced Cardiomyopathy, Aortic Valve Stenosis
Interventions
Right ventricular septal pacing followed by left bundle branch area pacing, Left bundle branch area pacing followed by right ventricular septal pacing
Device
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Ridgewood, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Not applicable Interventional

Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna

NCT00705913
View directory record Official record
Conditions
Aortic Valve Disease
Interventions
Mitroflow Aortic Pericardial Heart Valve (CarboMedics), Carpentier-Edwards Magna Tissue Valve
Device
Lead sponsor
Sorin Group USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
San Diego, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Prehabilitation for Patients Undergoing Transcatheter Aortic Valve Replacement

NCT03107897
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Pre-habilitation
Other
Lead sponsor
WellSpan Health
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve

NCT02097420
View directory record Official record
Conditions
Mitral Valve Disease, Damaged Mitral Valve, Malfunctioning Mitral Heart Valve, Mitral Valve Replacement
Interventions
Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Up to 5 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

NCT06680427
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)
Device
Lead sponsor
MiRus
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

The TRICURE EFS Study

NCT06506942
View directory record Official record
Conditions
Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Interventions
Transcatheter Tricuspid Valve Replacement
Device
Lead sponsor
TRiCares
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional

A pragmatiC sTrategy to Promote actIVity and Enhance Quality of Life AFTER Transcatheter Aortic Valve Replacement

NCT03270124
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Daily Activity Goal, Resistance Exercises, Daily Activity Recording
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Morristown, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

NCT03042104
View directory record Official record
Conditions
Heart Diseases, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
74
States / cities
Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

NCT00448864
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Ecallantide, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Not applicable Interventional Results available

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

NCT03517436
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
TAVR with CENTERA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Not applicable Interventional

A STEP for Patients Prior to Undergoing TAVR: A Pilot Study

NCT02766075
View directory record Official record
Conditions
Frail Elderly, Aortic Valve Stenosis
Interventions
Supervised TAVR Exercise Program
Behavioral
Lead sponsor
OSF Healthcare System
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 11, 2026, 4:37 AM EDT
Withdrawn Not applicable Interventional

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NCT05409378
View directory record Official record
Conditions
Aortic Regurgitation
Interventions
The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
Device
Lead sponsor
HLT Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 11, 2026, 4:37 AM EDT